Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.

Oncotarget - 8 Nov 2016

Deniziaut Gabrielle, Tille Jean Christophe, Bidard François-Clément, Vacher Sophie, Schnitzler Anne, Chemlali Walid, Trémoulet Laurence, Fuhrmann Laetitia, Cottu Paul, Rouzier Roman, Bièche Ivan, Vincent-Salomon Anne

Abstract excerpt

ERBB2 and ERBB3 somatic gain-of-function mutations, which may be targeted by anti-ERBB2 therapies, were reported by high-throughput sequencing studies in 1% and 2% of invasive breast cancers respectively. Our study aims to determine ERBB2 and ERBB3 mutations frequencies in grade 3 and/or ERBB2-positive invasive lobular breast carcinomas (ILC). All the 529 ILC surgically-excised registered at Institut Curie in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Lobular

Share to DNA Mutational Analysis

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Prognosis

Share to Receptor, ErbB-2

Source

Open in PubMed Open full text

Identifiers

PMID: 27602491
DOI: 10.18632/oncotarget.11819
PMCID: PMC5341983

Genes

ERBB2
ERBB3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.PMID 27602491Read ↗

ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high‐risk characteristics by molecular expression profilingSemantic proximity Read ↗

Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in ERBB2-Mutated Breast Cancer: In Silico Analysis.Semantic proximity Read ↗

Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.Semantic proximity Read ↗

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.Semantic proximity Read ↗

Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas.Semantic proximity Read ↗

High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic FeaturesSemantic proximity Read ↗

Mutations in ERBB3 drive tumorigenesis.Semantic proximity Read ↗

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors.Semantic proximity Read ↗

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Semantic proximity Read ↗

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.Semantic proximity Read ↗

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid CancersSemantic proximity Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.